Online inquiry

IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ474MR)

This product GTTS-WQ474MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ474MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6767MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ8749MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ15071MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ11699MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ15478MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ10533MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ1462MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ14274MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW